Irish medtech company Aerogen has announced details of a €300 million scaling and investment plan, which will result in the creation of 725 new jobs in Ireland over the next 10 years.
Aerogen is Ireland’s largest indigenous medtech company and Enterprise Ireland’s largest client company in the sector having firmly established itself as a global leader in acute care aerosol drug delivery.
'Superb Partner'
“We are delighted to announce this continued expansion of Aerogen as a truly global life science company," said CEO and Founder of Aerogen, John Power.
"Enterprise Ireland have been a superb partner in supporting this journey on which we just reached the pivotal milestone of having treated our 25th millionth patient, and we will continue to innovate across the respiratory journey for patients from our HQ here in Galway.”
Investment Plan
The Aerogen Group is headquartered in Dangan, Galway and the new Irish jobs will be across R&D, manufacturing, science and engineering and located there and at its two manufacturing sites in Parkmore, Galway and in Shannon.
The implementation of the plan will enable Aerogen to create up to 725 highly skilled jobs in the West by 2035 increasing its global workforce to over 2,000 of which over 1,100 will be based in Ireland.
As part of the ten-year scaling and investment plan, Aerogen aims to accelerate its existing device technology through new product innovation and leveraging of global opportunities.
Simultaneously, it will build its emerging biopharmaceutics business with treating premature newborns with Infant Respiratory Stress Syndrome. The team at Aerogen say high quality R&D is crucial to its goal to become a global leader in pulmonary medicine and biopharmaceutics delivery, combined with a commitment to improving patient care through cutting-edge technologies.
Development
Aerogen has been growing at over 20% per annum for the last decade with annual revenues now over €150 million and has contributed €130 million to local Irish businesses in the time.
Over the next five years Aerogen expects to contribute a further €250 million in income and corporation taxes, directly benefiting the Irish economy.
'Patient-Focused Mission'
“The government through Enterprise Ireland is targeting ambitious scaling of Irish multinationals that will help drive the Irish economy and our competitive advantage forward," said Minister for Enterprise, Trade and Employment, Peter Burke.
"Aerogen’s announcement today is evidence of that Irish multinational ambition in action, and we are delighted to support them on their patient-focused mission."
